West Pharmaceutical Services (WST) Net Cash Flow (2009 - 2026)

West Pharmaceutical Services has disclosed Net Cash Flow across 18 years of filings, most recently posting -$84.0 million for Q2 2026.

• In Q2 2026, Net Cash Flow fell 196.55% year-over-year to -$84.0 million; the TTM figure through Jun 2026 stood at -$59.8 million (down 224.32% YoY), while the FY2025 annual figure was $283.8 million, up 181.58% from the prior year.
• Net Cash Flow came in at -$84.0 million for Q2 2026 at West Pharmaceutical Services, up from -$261.5 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $163.3 million in Q4 2025 to a low of -$261.5 million in Q1 2026.
• Average Net Cash Flow over 5 years is -$17.7 million, with a median of $700000.0 recorded in 2023.
• Year-over-year, Net Cash Flow plunged 1522.67% in 2024 and jumped 895.73% in 2025.
• Over 5 years, Net Cash Flow stood at $126.5 million in 2022, then tumbled by 146.8% to -$59.2 million in 2023, then soared by 127.7% to $16.4 million in 2024, then jumped by 895.73% to $163.3 million in 2025, then sank by 151.44% to -$84.0 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$84.0 million in Q2 2026, -$261.5 million in Q1 2026, and $163.3 million in Q4 2025.